Cancer Needs a Robust "Metadata Supply Chain" to Realize the Promise of Artificial Intelligence.

Journal: Cancer research
Published Date:

Abstract

Profound advances in computational methods, including artificial intelligence (AI), present the opportunity to use the exponentially growing volume and complexity of available cancer measurements toward data-driven personalized care. While exciting, this opportunity has highlighted the disconnect between the promise of compute and the supply of high-quality data. The current paradigm of ad-hoc aggregation and curation of data needs to be replaced with a "metadata supply chain" that provides robust data in context with known provenance, that is, lineage and comprehensive data governance that will allow the promise of AI technology to be realized to its full potential in clinical practice.

Authors

  • Caroline Chung
    The University of Texas MD Anderson Cancer Center, Houston, TX.
  • David A Jaffray
    Radiation Medicine Program, Princess Margaret Cancer Centre, Toronto, Ontario M5G 2M9, Canada; Department of Radiation Oncology, University of Toronto, Toronto, Ontario M5S 3E2, Canada; and Techna Institute, University Health Network, Toronto, Ontario M5G 1P5, Canada.